Related references
Note: Only part of the references are listed.Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics
Satoshi Nagata et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
B. J. Stish et al.
BRITISH JOURNAL OF CANCER (2009)
A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma
Seunguk Oh et al.
CLINICAL CANCER RESEARCH (2009)
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery
Seunguk Oh et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model
Brad J. Stish et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results
Michael A. Vogelbaum et al.
NEUROSURGERY (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter
Seunguk Oh et al.
JOURNAL OF NEUROSURGERY (2007)
Lessons learned in the development of targeted therapy for malignant gliomas
Antonio M. P. Omuro et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv
Brad J. Stish et al.
CLINICAL CANCER RESEARCH (2007)
Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice
Edward Rustamzadeh et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
Masanori Onda et al.
JOURNAL OF IMMUNOLOGY (2006)
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13
Edward Rustamzadeh et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms
M Salajegheh et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma
DA Vallera et al.
CLINICAL CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice
DA Vallera et al.
LEUKEMIA RESEARCH (2005)
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma
IF Parney et al.
JOURNAL OF NEUROSURGERY (2005)
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model
DA Todhunter et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2004)
Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells
GW Prager et al.
BLOOD (2004)
Diphtheria toxin-epidermal growth factor fusion protein and pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells
TF Liu et al.
BIOCONJUGATE CHEMISTRY (2003)
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
O Engebraaten et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor
T Mori et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
Share Paper
